FDA approves new drug to protect babies from RSV
CBSN
The Food and Drug Administration announced Monday it had approved a new kind of immunization to protect babies from RSV, or respiratory syncytial virus. The drug, nirsevimab, is one of two new options doctors hope could soon prevent the leading cause of hospitalization facing American infants.
Outside advisers to the federal government have previously hailed nirsevimab's showing in clinical trials as potentially "groundbreaking" for protecting babies. A panel of the FDA's outside experts voted in June to back the drug's safety and efficacy.
"Today's approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system," the FDA's Dr. John Farley, director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research, said in a statement.
We just had another election with a clear and verifiable victor, overseen by hundreds of thousands of election officials. Those public servants have suffered years of harassment, and despite their successes, are still being accused of taking part in a massive and impossible conspiracy — a conspiracy led by the party out of power to steal an election and cover up all evidence.
Washington — Former Republican Rep. Matt Gaetz is meeting with senators on Capitol Hill on Wednesday as he seeks to shore up support for his nomination for attorney general amid calls for the House Ethics Committee to release a report on allegations he engaged in sexual misconduct and illicit drug use.